PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3.
- PhaseBio licensed bentracimab from AstraZeneca plc (NASDAQ:AZN), the maker of blood thinner Brilinta (ticagrelor), in 2017.
- It is a monoclonal antibody fragment that counters the effects of Brilinta by binding to the drug and its active metabolite.
- Under the deal, BioVectra will manufacture the active ingredient of bentracimab for use in those clinical trials and commercialization if it’s approved.
- Price Action: PHAS shares increased 2.6% at $4.17 in market trading hours on the last check Thursday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
